The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Self-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Cited by
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
Bodor, J. N., Boumber, Y., & Borghaei, H. (2020) · Cancer · doi:10.1002/cncr.32468 · Cited by 329
Best, M. G., Wesseling, P., & Wurdinger, T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0887 · Cited by 297
Peng, L., Wang, Y., Liu, F., Qiu, X., Zhang, X., Fang, C., Qian, X., & Li, Y. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02585-w · Cited by 266
Fucà, G., Galli, G., Poggi, M., Lo Russo, G., Proto, C., Imbimbo, M., Ferrara, R., Zilembo, N., Ganzinelli, M., Sica, A., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000457 · Cited by 209
Zhang, N., Jiang, J., Tang, S., & Sun, G. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106677 · Cited by 109
(2019) · PubMed Central · doi:10.22088/cjim.10.3.320 · Cited by 57
“marker as well as a significant prognostic factor for disorders such as cardiovascular diseases (8), different types of malignancies (9-12) and inflammatory bowel disease (IBD) (13).”
BackgroundMathur, K., Kurbanova, N., & Qayyum, R. (2019) · Platelets · doi:10.1080/09537104.2019.1571188 · Cited by 55
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer.
Bittoni, A., Pecci, F., Mentrasti, G., Crocetti, S., Lupi, A., Lanese, A., Pellei, C., Ciotti, C., Cantini, L., Giampieri, R., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-3499 · Cited by 42
Castello, A., Rossi, S., Toschi, L., & Lopci, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061251 · Cited by 36
Ucuz, İ., & Kayhan Tetik, B. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110061 · Cited by 27
Metadata
- Authors
- Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., Templeton, A. J., & Früh, M.
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 111
- Pages
- 176-181
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W2737656823
- Cited by
- 986
- References
- 36
- FWCI
- 26.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.